nmCRPC
Non-metastatic castration-resistant prostate cancer
Advertisement
Darolutamide in nmCRPC shows deep PSA responses but some radiographic progression despite low PSA levels.
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
A clinical trial sought to determine if flutamide is more effective with or without PROSTVAC in patients with nmCRPC.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.
Researchers conducted a study to determine PSA response and MFS in patients with nmCRPC treated with APA.
Existing literature on adverse events in ARSi drugs was examined to determine how the drugs’ side-effect profiles compare.
The first report on preoperative NLR in predicting nodal involvement for patients with non-metastatic prostate cancer.
A team of researchers examined the effect of cholesterol on androgen receptor coactivators for CRPC in vitro and in vivo.
Zoledronic acid did not improve survival outcomes in patients outside of metastatic castration-resistant disease.
Several factors may be associated with risk for falls among nmCRPC patients treated with apalutamide and ongoing ADT.
An NNH analysis of 2nd generation androgen receptor inhibitors for nmCRPC showed a trend toward higher NNH for darolutamide.
Dr. Neal Shore presents the impressive updates for the results of the Aramis trial.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.